Blockade of peanut allergy with a novel Ara h 2–Fcγ fusion protein in mice
Y Liu, Y Sun, LJ Chang, N Li, H Li, Y Yu… - Journal of allergy and …, 2013 - Elsevier
BACKGROUND: Conventional immunotherapy for peanut allergy using crude peanut
extracts is not recommended because of the unacceptably high risk of anaphylaxis. Allergen-
specific immunotherapy is not currently undertaken for peanut allergy. OBJECTIVES: The
objective of this study was to develop a novel peanut-human fusion protein to block peanut-
induced anaphylaxis. METHODS: We genetically designed and expressed a novel plant-
human fusion protein composed of the major peanut allergen Ara h 2 and human IgG Fcγ1 …
extracts is not recommended because of the unacceptably high risk of anaphylaxis. Allergen-
specific immunotherapy is not currently undertaken for peanut allergy. OBJECTIVES: The
objective of this study was to develop a novel peanut-human fusion protein to block peanut-
induced anaphylaxis. METHODS: We genetically designed and expressed a novel plant-
human fusion protein composed of the major peanut allergen Ara h 2 and human IgG Fcγ1 …